Clinical trials: Rifampin
Healthy Participants
A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of AMG 510 alone and in combination with rifampin in healthy participants.
- Trial name
- NCT05577624
- Testing
- AMG 510, Rifampin
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Amgen
Tuberculosis, Multidrug-Resistant
Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis
Acquired drug-resistance is a major challenge for tuberculosis (TB) care programs. The 2020 WHO guidelines recommends replacing second-line injectables by bedaquiline in rifampicin-resistant TB (RR-TB) treatment regimens.
- Trial name
- Stake (NCT05555303)
- Testing
- Amikacin
- Where
- Rwanda
- Volunteers
- 20 people
- Sponsor
- Rwanda Biomedical Centre
Tuberculosis, Latent Tuberculosis
A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study)
This is a prospective, multi-center, open-label, cluster randomized controlled clinical trial conducted in school settings to estimate the non-inferiority effect of 1H3P3 compared with 3HR.
- Trial name
- TB-YOUTH (NCT06022146)
- Testing
- isoniazid and rifapentine, Rifampin and Isoniazid
- Where
- 66 sites in China
- Volunteers
- 3,520 people
- Sponsor
- Huashan Hospital
Healthy Participants
A Phase I Clinical Trial to Evaluate Pharmacokinetics of HS-10504
This is a single-center, open-label, fixed-sequence, self-controlled Phase I clinical study with a planned enrollment of approximately 18 healthy participants.
- Trial name
- NCT07770217
- Testing
- HS-10504, Rifampin
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Pulmonary Tuberculosis
Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis
The purpose of this study is to assess the safety, early bactericidal activity (EBA) and pharmacokinetics of TBA-7371 in adult participants with rifampicin-sensitive tuberculosis and select dose regimen(s) for future studies.
- Trial name
- NCT04176250
- Testing
- TBA-7371, HRZE
- Where
- 4 sites in South Africa
- Volunteers
- 93 people
- Sponsor
- Gates Medical Research Institute
Drug Resistant Tuberculosis
Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment
The goal of the BringBPaL2Me Trial, a multi-principal investigator, multi-site, cluster randomized, non-inferiority trial is to compare nurse-led RR-TB treatment in primary care clinics to standard of care physician-led RR-TB…
- Trial name
- NCT05671718
- Testing
- Nurse-Led Treatment in Primary Care
- Where
- 5 sites in South Africa
- Volunteers
- 2,944 people
- Sponsor
- Johns Hopkins University
Pulmonary TB
Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease
RIFAstrat is a Phase 3, double-blind, placebo-controlled, non-inferiority trial to compare the 6-month standard treatment for DS-TB with a 4-month optimised- rifampicin based regimen provided to individuals with limited disease…
- Trial name
- RIFAstrat (NCT07118696)
- Testing
- Extra 600mg of Rifampicin
- Volunteers
- 1,000 people
- Sponsor
- Hamilton Health Sciences Corporation
Tuberculous Meningitis
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
The purpose of this study is to compare a 6-month regimen of high-dose rifampicin (RIF), high-dose isoniazid (INH), linezolid (LZD), and pyrazinamide (PZA) versus the World Health Organization (WHO) standard of care (SOC)…
- Trial name
- NCT05383742
- Testing
- Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD)
- Where
- 18 sites in Brazil, India and 10 more
- Volunteers
- 330 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Relapsed or Refractory Lymphoma
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
An open-label study to determine effect of Itraconazole, Fluconazole, Rifampin, and Rabeprazole on the PK of HMPL-689
- Trial name
- NCT05602597
- Testing
- Itraconazole 200 mg, Fluconazole 400 mg, Rifampin 600 mg
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Latent Tuberculosis
Implementation of an Integrated Care Strategy for Children Contacts of Patients With Tuberculosis
Introduction: childhood tuberculosis continues to be a major public health problem, despite the fact that the visibility of the epidemic in this population group has increased, studies are still lacking that can resolve the gaps…
- Trial name
- NCT04331262
- Where
- Colombia
- Volunteers
- 163 people
- Sponsor
- Corporacion para Investigaciones Biologicas
Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, SHR1459
Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)
This drug-drug interaction (DDI) study had been designed to investigate the effect of a strong CYP 3A index fan-inducer rifampicin on the pharmacokinetics of SHR1459 in Chinese healthy volunteers.
- Trial name
- NCT04649723
- Testing
- Rifampin, SHR1459
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rifampicin Capsules (RIF)
Azvudine(FNC)，a nucleoside reverse transcriptase inhibitor, make itself a better candidate to be co-formulated in other anti-HIV therapies, thus to improve patient's compliance.
- Trial name
- NCT07002255
- Testing
- Azvudine tablets(FNC) and Rifampicin Capsules (RIF)
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Henan Genuine Biotech Co., Ltd.
Solid Tumours
To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
Study to assess the effect of Rifampicin on the pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
- Trial name
- NCT02046850
- Testing
- selumetinib, rifampicin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Kidney Disease, Tuberculosis
A Pilot Study for Pharmacokinetic Parameter of Colchicine in Patient Taking Rifampin
The purpose of this study is to examine the colchicine concentration before and after the administration of rifampicin.
- Trial name
- NCT01932268
- Testing
- Rifampicin
- Volunteers
- 2 people
- Sponsor
- Seoul National University Hospital
Tuberculosis, Drug-resistant Tuberculosis
Evaluation of Centralised TB Assay Solutions
Tuberculosis (TB) remains a life-threatening disease partly due to increasing incidence of multidrug and extensively drug-resistant TB.
- Trial name
- NCT04147676
- Where
- 6 sites in Georgia, Germany and 3 more
- Volunteers
- 1,050 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Tuberculosis
PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay
PNU-100480 is being developed for the treatment of both drug resistant and sensitive tuberculosis. This is an efficacy and safety study to characterize the effect of PNU-100480 when given for 14 days to treatment-naive patients…
- Trial name
- NCT01225640
- Testing
- PNU-100480, RHZE
- Where
- 2 sites in South Africa
- Volunteers
- 59 people
- Sponsor
- Sequella, Inc.
Healthy Adult Participants
A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions, and Pharmacokinetics of TBD11
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose trial of TBD11 in healthy adults. It includes a dedicated open-label cohort in which TBD11 will be administered as a single dose with either a strong…
- Trial name
- NCT07883226
- Testing
- TBD11 (300 mg), Itraconazole (200 mg), Rifampicin 600mg
- Where
- South Africa
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Uveitis, Anterior
Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA)
Uveitis accounts for 15% of the causes of legal blindness. The etiological diagnosis of uveitis is difficult because of the poor bacteriological performance of aqueous or vitreous fluid analysis.
- Trial name
- URBA (NCT04117698)
- Testing
- Antitubercular treatment (RIFATER ©), Ethambutol, RIFINAH ©
- Volunteers
- 116 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
AIDS With Tuberculosis
Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes
Tuberculosis (TB) is a leading cause of death in HIV-infected individuals. There are insufficient data correlating concentrations of anti-TB drugs with treatment response.
- Trial name
- SOUTH (NCT01782950)
- Testing
- Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
- Where
- Uganda
- Volunteers
- 400 people
- Sponsor
- Makerere University
Tuberculosis, Pulmonary, AIDS
Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis
To compared the efficacy and safety of rifampicin and rifabutin which included in the standard treatment of anti-tuberculosis in HIV/AIDs patients combined with pulmonary tuberculosis, a multi-center, prospective cohort will be…
- Trial name
- RRHT (NCT03478033)
- Testing
- Rifampicin, Rifabutin
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Shanghai Public Health Clinical Center